Earnings summaries and quarterly performance for ELUTIA.
Executive leadership at ELUTIA.
Board of directors at ELUTIA.
Research analysts who have asked questions during ELUTIA earnings calls.
Recent press releases and 8-K filings for ELUT.
ELUTIA reports Q3 2025 results and completes BioEnvelope business sale
ELUT
Earnings
M&A
New Projects/Investments
- Elutia completed the $88 million cash sale of its BioEnvelope business on October 1, 2025, which generated $49 million in net cash proceeds at closing.
- For Q3 2025, the company reported net sales of $3.3 million, a GAAP gross margin of 55.8%, and an adjusted gross margin of 63.9%.
- The loss from operations for Q3 2025 was $5.2 million, and the adjusted EBITDA loss remained approximately unchanged at $2.7 million compared to Q3 2024.
- Elutia is now strategically focusing its validated technology platform on the $1.5 billion breast reconstruction market with its NXT-41x product, supported by its current cash balance of $4.7 million plus the $49 million net proceeds from the BioEnvelope sale to fund future development and commercialization.
Nov 6, 2025, 10:00 PM
Elutia Reports Q3 2025 Financial Results and Strategic Updates
ELUT
Earnings
M&A
New Projects/Investments
- Elutia completed the sale of its bio-envelope business, including Eliupro and Kangaroo products, to Boston Scientific for $88 million, with the transaction closing on the first day of Q4 2025. This generated $49 million in cash after debt payoff and deal expenses, providing a financial runway through the commercial launch of NXT 41 and 41X in 2026 and 2027.
- For Q3 2025, continuing operations reported $3.3 million in overall sales, driven by $2.4 million from SimpliDerm (up 18% sequentially) and $0.9 million from cardiovascular products (up 68% year-over-year). The adjusted EBITDA loss for the quarter was $2.7 million.
- The company is advancing the development of NXT 41 and NXT 41X for the $1.5 billion breast reconstruction market, targeting NXT 41 approval in the second half of 2026 and NXT 41X approval in the first half of 2027.
- Elutia resolved seven legacy fiber cell litigation cases in Q3 2025, reducing the remaining cases to six with an estimated liability of approximately $700,000.
Nov 6, 2025, 10:00 PM
Elutia Reports Q3 2025 Results and BioEnvelope Business Sale
ELUT
Earnings
M&A
New Projects/Investments
- Elutia Inc. reported Q3 2025 net sales of $3.3 million and a net loss of $3.868 million, with an adjusted EBITDA loss of $2.742 million.
- The company completed the sale of its BioEnvelope business to Boston Scientific Corporation for $88 million on October 1, 2025, using the $80.3 million in proceeds received to eliminate $27.8 million in debt and fund the NXT-41x development program.
- Elutia is advancing NXT-41x, an antibiotic-eluting biomatrix targeting an estimated $1.5 billion U.S. market opportunity in plastic and reconstructive surgery, with FDA clearance for the base matrix anticipated in 2H26 and the drug-eluting version in 1H27.
- Guido J. Neels was appointed to the Company’s Board of Directors.
Nov 6, 2025, 9:15 PM
Aleutia Highlights Validated Technology and Financial Strength for Breast Reconstruction Market
ELUT
Product Launch
New Projects/Investments
M&A
- Aleutia's drug-eluting biological envelope technology was validated by the sale of its Elupro product to Boston Scientific for $88,000,000 on October 1. This transaction represented approximately eight times revenue.
- The company is now applying this proven technology to the $1.5 billion breast reconstruction market with its NXT 41 product, aiming to address a significant unmet medical need where postoperative infection rates range from 15% to 21%.
- Aleutia generates $12,000,000 in annual revenue from existing biological products and is fully funded through the development, launch, and commercialization of NXT 41 without requiring additional capital.
- The company plans to file for FDA clearance of the NXT 41 matrix in H1 2026, with expected clearance around Q3 2026, and anticipates approval for the matrix with antibiotics in H1 2027.
Oct 21, 2025, 8:00 PM
Elutia Outlines Strategy for Drug-Eluting Biologics in Breast Reconstruction Market
ELUT
Product Launch
New Projects/Investments
M&A
- Elutia specializes in drug-eluting biologics, combining biological scaffolds with active pharmaceutical substances to humanize medicine and offer superior patient outcomes.
- The company successfully developed and gained FDA approval for its first drug-eluting biological envelope, EluPro, which was subsequently sold to Boston Scientific for $88 million.
- Elutia is now targeting the $1.5 billion breast reconstruction market with its NXT41/NXT41X product, utilizing the same proven technology to address the 15% to 21% post-operative infection rate.
- With approximately $12 million in annual revenue and sufficient cash from the EluPro sale, Elutia is fully resourced to fund the development and commercialization of NXT41/NXT41X without needing additional capital.
- Regulatory filings for the NXT41 matrix are planned for the first half of 2026, with clearance expected around the third quarter of 2026, followed by approval for the combination product (NXT41X) in the first half of 2027.
Oct 21, 2025, 8:00 PM
Elutia Completes Sale of BioEnvelope Business to Boston Scientific for $88 Million
ELUT
M&A
Debt Issuance
New Projects/Investments
- Elutia Inc. (ELUT) completed the sale of its BioEnvelope business, also known as the Device Protection segment or CIED Business, to Boston Scientific Corporation for $88 million in cash on October 1, 2025.
- The company received net cash proceeds of approximately $80.3 million, with an additional $8.0 million held in escrow.
- Elutia used approximately $27.8 million of the proceeds to repay its term loan facility in full.
- The sale will be classified as a discontinued operation, allowing Elutia to focus on advancing its NXT-41x platform for breast reconstruction, with a planned market launch in the first half of 2027.
Oct 7, 2025, 9:00 PM
Elutia Q1 2025 Earnings Report: Financial Results & Product Momentum
ELUT
Earnings
Revenue Acceleration/Inflection
Product Launch
- EluPro sales surged 84% sequentially and BioEnvelope revenue grew 31% YoY to $3.1M, showcasing strong product momentum .
- A new Boston Scientific distribution partnership has been established to accelerate product adoption, with early sales in over 50 hospitals .
- Q1 2025 financials include net sales of $6.0M (down from $6.7M YoY), operating expenses improved to $10.4M versus $11.3M, and a reduced adjusted EBITDA loss of $3.3M compared to $4.5M, with a cash balance of $17.4M as of March 31, 2025 .
May 8, 2025, 9:00 PM
Elutia Reports Q4 2024 Financial & Strategic Updates, EluPro Pilot Launch Success
ELUT
Earnings
Product Launch
Revenue Acceleration/Inflection
Legal Proceedings
- Q4 2024 Financial Performance: Revenue of $5.5M (annual $24.4M) with GAAP gross margin at 43% (up from 36%) and adjusted margin at 58% (up from 51%)
- EluPro Success: FDA-cleared EluPro shows strong clinical uptake—contributing about 30% of BioEnvelope sales with a 65% sales increase when centers switched from CanGaroo
- Reported robust Q4 and full year financial results with high demand for EluPro following its successful pilot launch; secured 67 approved EluPro accounts and key group purchasing agreements
- Strategic Partnerships: Expanded market reach via collaboration with Boston Scientific, leveraging 900 reps and increasing hospital VAC approvals from 100 centers
- Robust Cash Position: Maintained strong balance with $13.2M on hand and registered direct offering gross proceeds of $15.0M
- Litigation Update: Notable reduction in FiberCel litigation liability—from over $20M to $15.9M with outstanding cases falling from 79 to 43
Mar 6, 2025, 12:00 AM
ELUTIA INC. Q4 2024 8-K Update & $15 Million Registered Direct Offering
ELUT
Earnings
- Elutia Inc. announced a registered direct offering of 5,520,000 shares at $2.50 per share and 480,000 pre‑funded warrants at $2.499 each, generating approximately $15.0 million, expected to close on February 4, 2025 .
- Lake Street Capital Markets is the exclusive placement agent, with proceeds intended for working capital and general corporate purposes .
- On February 3, 2025, Elutia Inc. filed its Form 8‑K for Q4 2024, detailing current operational and financial conditions .
- The filing provides preliminary net sales estimates for the year ended December 31, 2024, covering device protection, women’s health, and cardiovascular segments .
- It includes extensive forward‑looking statements outlining risks and uncertainties, and was signed by CFO Matthew Ferguson .
Quarterly earnings call transcripts for ELUTIA.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more